Fibrogen Inc CS (FGEN)

$11.18 +0.09 (0.81%)
Market Cap 44.85M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio -0.36
Volume 33,500
Avg Vol 62,681
Day's Range N/A - N/A
Shares Out 4.04M
Stochastic %K 80%
Beta 0.76
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 23 at 5:58 AM
$FGEN https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-025-02378-6
0 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 22 at 6:21 PM
$FGEN In the stock market (and in business accounting in general), Q3 refers to the third quarter of the calendar year, which covers July 1 through September 30. Counting weekdays (and subtracting Labor Day), there are 25 business days before September 30, 2025.
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 22 at 1:58 PM
$FGEN read it on page 11 https://watermark02.silverchair.com/sfaf252.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA2AwggNcBgkqhkiG9w0BBwagggNNMIIDSQIBADCCA0IGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMxlGEutBbpDBFkULPAgEQgIIDExnoKa_Qxq4tua7fwS8G9mhdAVUnyGHRIpfoonKiod-gR9yrs4NJmGmxVxe3lejrFh_31D5gii7_kuk1McLRcVflmVSia78i8OsRmX0MiKLhspSCZYYVuw29XcR0uyOPNGunb2EIOJC3iR-DuOGji4YKifp9IIm48zHbPzPbinHKkj23WVCxJuNQOo7MW8KDYmB1IVL_jRCuD_cGKWIxjIC4XzZ7UW972ERrUGQ7h1uwmcZk0WreoOUtxEDTtmALQ-Onm_tXkC9FyuTRwY-9pZZEeMYHSLRQESqqiJhtrEmZJdysaz-KXdD_d6yKqNQQWyY1jJuPMfm0IFd2Qnv2-Id2sY5WFmthEsxXd4SBdwbXrUDZiELR0lJWQB1tR6PT1Fzbqp4bahayFrrikWAuY7xhmTo2OtWewUnaQiVHdHgd0Oqq-w4JLBQVpiWjRsg4AB4trvnzoCrzMRD7bCNizO1v8cM-4K1vk6SjLqjmc4q1YVY9UJszjo2KkVow2joqpd8_QGP1WYlH0ivLfn9sKZAou5WDBdtrEQGgUfOgx2TBfZr1WAQBwdy77ELDCeReBH50JEYRoQw6HsLbux-5eb18mOTkGMYw9jKPjAHCA8Nul_qn3DPLJv93gVFHV1NDhDSOOvsyFddjeE7nCTxxg5bYOc1eSziPa7dIThBMMzQv0ZP-ZhjogPU03JrC4_RN4G8DA41Oamh7NKsaBsP6aOFU3kJQHRQomfp2ZcrHnmkqH_fSNVzKZk2Hqw7kfCn6l-d1v9xHwhBIdqgRsBtC-O_938Fx5mbBNxNt7gO3DVctP11Nc4yQ3gVxJO3IoWtMgFiKHnq8Xm7Ki5Va229cRW8UNZo7msGcRyJrExLjoEkvgmCSkzkO0_9v7RW0-d-XWxPG3JaQbzr1DLOHrSicCXzHvLAjK2E3lsack2cJnABklsaB6ogkX3xWmJv6nPRwPb70TPQY2ThcVqLa_p-eCHljA1iKp3YQRatSEFuUJSkUd2pFHiJMfb7NomA2b7rMQbmeYas0GeSkMtDXQI-81HgmLZw
2 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 22 at 12:02 PM
$FGEN Just look at how many funds bought a lot of stocks in August. https://fintel.io/so/us/fgen
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 22 at 11:02 AM
$FGEN Correct me if I'm wrong. Do I understand correctly that Armistice Capital has doubled its stake in Fibrogen shares? See the link https://fintel.io/so/us/fgen/armistice-capital-llc It says here that they own 8,500,000 shares on 2025-05-15. After RS, there should have been 340,000 shares. On August 15, Armistice Capital announced that it owns 723,092 shares, which is 383,092 more. This means that they have more than doubled their share. But why is there no message about such a purchase?
1 · Reply
Kalns
Kalns Aug. 22 at 10:05 AM
$FGEN 🙌
0 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 21 at 1:18 PM
$FGEN While Evrenzo's path to approval for CKD-related anemia is currently uncertain due to the FDA's concerns, FibroGen is actively pursuing approval for the drug in the LR-MDS indication, which has received positive support from the FDA.
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 21 at 11:43 AM
$FGEN two more recent news about roxadustat, the links are just below on this board. The citation on the Internet about roxadustat is growing.
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 21 at 11:39 AM
$FGEN https://www.renalandurologynews.com/news/red-blood-cell-lifespan-affected-by-dialysis-patient-factors/
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 21 at 9:57 AM
$FGEN https://journals.lww.com/cmj/fulltext/9900/lower_vs__standard_starting_dose_oral_roxadustat.1704.aspx
1 · Reply
Latest News on FGEN
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 18, 2025, 7:00 AM EDT - 5 days ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:55 PM EDT - 11 days ago

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:02 PM EDT - 11 days ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

FibroGen to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 4:02 PM EDT - 18 days ago

FibroGen to Report Second Quarter 2025 Financial Results

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 13, 2025, 8:22 AM EDT - 2 months ago

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ADBE

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 2 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

Jun 9, 2025, 4:02 PM EDT - 2 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:31 PM EDT - 3 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:02 PM EDT - 3 months ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 8, 2025, 4:24 AM EDT - 3 months ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 3 months ago

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 5 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:18 PM EDT - 5 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 5 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 6 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

Feb 20, 2025, 1:08 PM EST - 6 months ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

AZN

FibroGen sells China unit to AstraZeneca in deal worth $160 million

Feb 20, 2025, 6:40 AM EST - 6 months ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Feb 20, 2025, 6:30 AM EST - 6 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 8 months ago

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 8:38 PM EST - 10 months ago

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 10 months ago

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 10 months ago

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 31, 2024, 12:33 PM EDT - 1 year ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 6, 2024, 12:38 PM EDT - 1 year ago

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:05 PM EDT - 1 year ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Jun 3, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 23, 2024, 5:05 PM EDT - 1 year ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apr 2, 2024, 5:46 PM EDT - 1 year ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:44 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 1 year ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:06 PM EST - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 26, 2024, 4:05 PM EST - 1 year ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:00 AM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Feb 5, 2024, 7:00 AM EST - 1 year ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 25, 2024, 7:00 AM EST - 1 year ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Dec 9, 2023, 5:02 PM EST - 1 year ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:30 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

FibroGen Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 4:01 PM EST - 1 year ago

FibroGen Reports Third Quarter 2023 Financial Results

FibroGen to Report Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 1 year ago

FibroGen to Report Third Quarter 2023 Financial Results

ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 23 at 5:58 AM
$FGEN https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-025-02378-6
0 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 22 at 6:21 PM
$FGEN In the stock market (and in business accounting in general), Q3 refers to the third quarter of the calendar year, which covers July 1 through September 30. Counting weekdays (and subtracting Labor Day), there are 25 business days before September 30, 2025.
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 22 at 1:58 PM
$FGEN read it on page 11 https://watermark02.silverchair.com/sfaf252.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA2AwggNcBgkqhkiG9w0BBwagggNNMIIDSQIBADCCA0IGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMxlGEutBbpDBFkULPAgEQgIIDExnoKa_Qxq4tua7fwS8G9mhdAVUnyGHRIpfoonKiod-gR9yrs4NJmGmxVxe3lejrFh_31D5gii7_kuk1McLRcVflmVSia78i8OsRmX0MiKLhspSCZYYVuw29XcR0uyOPNGunb2EIOJC3iR-DuOGji4YKifp9IIm48zHbPzPbinHKkj23WVCxJuNQOo7MW8KDYmB1IVL_jRCuD_cGKWIxjIC4XzZ7UW972ERrUGQ7h1uwmcZk0WreoOUtxEDTtmALQ-Onm_tXkC9FyuTRwY-9pZZEeMYHSLRQESqqiJhtrEmZJdysaz-KXdD_d6yKqNQQWyY1jJuPMfm0IFd2Qnv2-Id2sY5WFmthEsxXd4SBdwbXrUDZiELR0lJWQB1tR6PT1Fzbqp4bahayFrrikWAuY7xhmTo2OtWewUnaQiVHdHgd0Oqq-w4JLBQVpiWjRsg4AB4trvnzoCrzMRD7bCNizO1v8cM-4K1vk6SjLqjmc4q1YVY9UJszjo2KkVow2joqpd8_QGP1WYlH0ivLfn9sKZAou5WDBdtrEQGgUfOgx2TBfZr1WAQBwdy77ELDCeReBH50JEYRoQw6HsLbux-5eb18mOTkGMYw9jKPjAHCA8Nul_qn3DPLJv93gVFHV1NDhDSOOvsyFddjeE7nCTxxg5bYOc1eSziPa7dIThBMMzQv0ZP-ZhjogPU03JrC4_RN4G8DA41Oamh7NKsaBsP6aOFU3kJQHRQomfp2ZcrHnmkqH_fSNVzKZk2Hqw7kfCn6l-d1v9xHwhBIdqgRsBtC-O_938Fx5mbBNxNt7gO3DVctP11Nc4yQ3gVxJO3IoWtMgFiKHnq8Xm7Ki5Va229cRW8UNZo7msGcRyJrExLjoEkvgmCSkzkO0_9v7RW0-d-XWxPG3JaQbzr1DLOHrSicCXzHvLAjK2E3lsack2cJnABklsaB6ogkX3xWmJv6nPRwPb70TPQY2ThcVqLa_p-eCHljA1iKp3YQRatSEFuUJSkUd2pFHiJMfb7NomA2b7rMQbmeYas0GeSkMtDXQI-81HgmLZw
2 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 22 at 12:02 PM
$FGEN Just look at how many funds bought a lot of stocks in August. https://fintel.io/so/us/fgen
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 22 at 11:02 AM
$FGEN Correct me if I'm wrong. Do I understand correctly that Armistice Capital has doubled its stake in Fibrogen shares? See the link https://fintel.io/so/us/fgen/armistice-capital-llc It says here that they own 8,500,000 shares on 2025-05-15. After RS, there should have been 340,000 shares. On August 15, Armistice Capital announced that it owns 723,092 shares, which is 383,092 more. This means that they have more than doubled their share. But why is there no message about such a purchase?
1 · Reply
Kalns
Kalns Aug. 22 at 10:05 AM
$FGEN 🙌
0 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 21 at 1:18 PM
$FGEN While Evrenzo's path to approval for CKD-related anemia is currently uncertain due to the FDA's concerns, FibroGen is actively pursuing approval for the drug in the LR-MDS indication, which has received positive support from the FDA.
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 21 at 11:43 AM
$FGEN two more recent news about roxadustat, the links are just below on this board. The citation on the Internet about roxadustat is growing.
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 21 at 11:39 AM
$FGEN https://www.renalandurologynews.com/news/red-blood-cell-lifespan-affected-by-dialysis-patient-factors/
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 21 at 9:57 AM
$FGEN https://journals.lww.com/cmj/fulltext/9900/lower_vs__standard_starting_dose_oral_roxadustat.1704.aspx
1 · Reply
ibaian
ibaian Aug. 21 at 4:33 AM
$FGEN
0 · Reply
ibaian
ibaian Aug. 21 at 4:29 AM
$FGEN Approved $ 20 coming 🚀
0 · Reply
Value10
Value10 Aug. 20 at 5:18 PM
$FGEN When FGEN was at $5 a share… just weeks ago... some said that it was not low enough, best to wait. No it is double. 100% higher. 100% rate of return within weeks. So, when it is $20… will you still say $10 was too high, best to wait for a lower share price? What about when it is $80 after a partnership or Sale is announced? Is $10 still too high???
2 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 20 at 2:44 PM
$FGEN I may grab a few 100 shares or so if closer to $10 or below
0 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 20 at 2:37 PM
$FGEN Market+FGEN are bleeding hard
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 20 at 1:31 PM
$FGEN Maybe it seems to me. But it seems that recently, there have been more articles about ROXADUSTAT. At least two new articles, links below.
2 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 20 at 1:16 PM
$FGEN https://www.cureus.com/articles/389447#!/ .
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 20 at 1:15 PM
$FGEN https://www.nature.com/articles/s41598-025-16046-w .
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Aug. 19 at 7:47 PM
$FGEN The stock market is indeed in the red, and I'm curious about the upcoming news. Additionally, fibrogen's stock has been affected by the correction that followed yesterday's rise.
0 · Reply
Tika1
Tika1 Aug. 19 at 5:38 PM
$FGEN why I can’t buy this at Bank of America?
1 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 19 at 4:41 PM
$FGEN Per Invest.Us: The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 428.34% during the next 3 months and, with a 90% probability hold a price between $41.04 and $68.91 at the end of this 3-month period.
0 · Reply
MaxMiamiFl
MaxMiamiFl Aug. 19 at 3:10 PM
$FGEN Market is RED as hell, as of now
0 · Reply